Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022

Rhea-AI Summary

Veracyte, Inc. (Nasdaq: VCYT) announced it will release its third quarter 2022 financial results on November 2, 2022, after market close. Management plans to host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results and provide a business update. The call will be available via webcast on the company's website. Veracyte focuses on improving patient care with advanced diagnostic tests that help avoid unnecessary procedures and reduce treatment time, with operations based in South San Francisco, California.

Positive

• Scheduled Q3 2022 results release could indicate financial performance improvements.
• Focus on advanced diagnostics may enhance patient care and market position.

Negative

• None.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the third quarter of 2022 after the close of market on Wednesday, November 2, 2022. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/iigzqcix. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.

The conference call dial-ins can be accessed by registering at: https://register.vevent.com/register/BIdd8a25033ce74acb8bf03d2ed76733f0

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and reduce time to appropriate treatment. In addition to making our tests available in the United States through our central laboratories, our exclusive license to our best-in-class diagnostics instrument (nCounter Analysis System) positions us to deliver our tests to patients worldwide through laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

View source version on businesswire.com: https://www.businesswire.com/news/home/20221013005977/en/

Investors

Shayla Gorman - Director, Investor Relations

investors@veracyte.com

(619) 393-1545

Media

Tracy Morris - Vice President of Global Corporate Communications

tracy.morris@veracyte.com

(650) 380-4413

Source: Veracyte, Inc.

FAQ

When will Veracyte release its Q3 2022 financial results?

Veracyte will release its Q3 2022 financial results on November 2, 2022, after market close.

What time is Veracyte's conference call for Q3 2022 results?

The conference call will take place at 4:30 p.m. Eastern Time on November 2, 2022.

How can I access the Q3 2022 results conference call for Veracyte?

The Q3 2022 results conference call can be accessed via webcast on Veracyte's website.

What does Veracyte do?

Veracyte is a global diagnostics company that provides advanced diagnostic tests to improve patient care.